NCT07011095

DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial

A Pilot Trial to Assess the Feasibility of a Multicentre, Phase IV, Prospective, Randomized, Open-label, Two-arm Study With Blinded-endpoint Evaluation to Investigate Vitamin K Antagonist (VKA) Therapy Compared With Direct Oral Anticoagulant (DOAC) Therapy in Male and Female Participants With Atrial Fibrillation and Recent Ischemic Stroke While on a DOAC

• Status: Not Yet Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Population Health Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

People with atrial fibrillation who have a stroke while receiving a DOAC are at increased risk of experiencing another stroke. Physicians do not know the best medication to prevent another stroke in this group of people. Options include continuing the same DOAC, switching to another DOAC or switching to warfarin. The investigators of the SWITCH-AF trial are trying to find out whether switching to warfarin or continuing a DOAC is better for preventing stroke. The purpose of this study, called a pilot study, is to test the study plan and to find out whether enough participants will join a larger study that answers the question. A pilot study involves a small number of participants and it is not expected to tell us which treatment is better.

Conditions

• Atrial Fibrillation (AF)
• Stroke (in Patients With Atrial Fibrillation)

Interventions

Type	Name	Description
DRUG	VKA	Warfarin
DRUG	Direct Oral Anticoagulant (DOAC)	Locally approved DOACs

Timeline

• Start date: 2025-09-03
• Primary completion: 2027-02-03
• Completion: 2027-06-03
• First posted: 2025-06-08
• Last updated: 2025-06-08